Compare CSX Corporation (CSX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Johnson & Johnson — how do they compare? CSX Corporation trades at $50.05 (market cap $92.55B), while Johnson & Johnson trades at $260.8 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 6.8× CSX Corporation's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| CSX | JNJ | |
|---|---|---|
Market Cap | $92.55B | $626.09B |
Sector | Industrials | Health |
52-Week High | $53.21 | $267.24 |
52-Week Low | $32.05 | $172.78 |
Enterprise Value | $110.52B | $654.37B |
Dividend Yield | 1.12% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $50.12, down 0.3% on the day, with a neutral technical signal. Recent Q2 2026 earnings beat estimates with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and margin expansion. The stock's valuation ratios, including a P/E of 29.05 and P/S of 6.41, reflect a premium pricing relative to historical levels. Analyst consensus is bullish with a $52.57 price target, supported by 58.69% buy ratings.
The outlook for CSX is positive, with projected 2026 revenue growth and improved cash flow. Key opportunities include strong intermodal demand and operational efficiency gains. Risks involve competitive pressures, fuel cost volatility, and potential economic slowdowns affecting freight volumes. The stock's current level offers a moderate upside to the consensus target, balanced by elevated valuation multiples.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
